Literature DB >> 931182

Sources of Mycobacterium avium complex infection resulting in human diseases.

G Meissner, W Anz.   

Abstract

Human disease caused by organisms in the Mycobacterium avium complex occur virtually worldwide. A 20-year ongoing study conducted in Western Germany has been analyzed to elucidate the ecologic and epidemiologic characteristics of these infections in man. Organisms included in this investigation have been cultured from man, from domestic and wild animals and fowl, and from a variety of environmental sources. In addition to the usual taxonomic studies of these bacilli, infrasubspecific typing by seroagglutination has enabled identification of 3 distinct serogroups: the classical Mycobacterium avium strains (serovars avium 1, 2, and 3), the intermediate group (avium serovars 4, 5, 6, 8, 9, 10, and 11), and the less frequently encountered organisms, the 11 remaining avium serovars (7 and 12 through 21). Analysis of the number of strains in each of the 3 serogroups, derived, respectively, from man, from animals, and from the environment, has enabled us to draw some conclusions regarding reservoirs and sources of human infection with these agents.

Entities:  

Mesh:

Year:  1977        PMID: 931182     DOI: 10.1164/arrd.1977.116.6.1057

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  32 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Relationship between IS901 in the Mycobacterium avium complex strains isolated from birds, animals, humans, and the environment and virulence for poultry.

Authors:  I Pavlik; P Svastova; J Bartl; L Dvorska; I Rychlik
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  Characterization of isolates of Mycobacterium avium serotypes 4 and 8 from patients with AIDS by multilocus enzyme electrophoresis.

Authors:  M A Yakrus; M W Reeves; S B Hunter
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

4.  Restriction endonuclease analysis of members of the Mycobacterium avium-M. intracellulare-M. scrofulaceum serocomplex.

Authors:  B J Wards; D M Collins; G W de Lisle
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

5.  Identification and differentiation of Mycobacterium avium and M. intracellulare by PCR.

Authors:  Z H Chen; W R Butler; B R Baumstark; D G Ahearn
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

6.  Typing of clinical Mycobacterium avium complex strains cultured during a 2-year period in Denmark by using IS1245.

Authors:  J Bauer; A B Andersen; D Askgaard; S B Giese; B Larsen
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  Geographic distribution, frequency, and specimen source of Mycobacterium avium complex serotypes isolated from patients with acquired immunodeficiency syndrome.

Authors:  M A Yakrus; R C Good
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

8.  Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics.

Authors:  T E Kiehn; F F Edwards; P Brannon; A Y Tsang; M Maio; J W Gold; E Whimbey; B Wong; J K McClatchy; D Armstrong
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Two children with extra-nodal Mycobacterium avium complex infection.

Authors:  Ali Markland; Ben Tan; Darryl Adamko; Tania Diener; Paul N Levett; Sheldon Wiebe; Hui Wang; Mark Podberezin; Krysztof Saczek; Kris Milbrandt; Abdulhafid Essalah; William Quan; Harry Deneer
Journal:  Paediatr Child Health       Date:  2020-05-27       Impact factor: 2.253

10.  Deficiency of immunity to Mycobacterium avium that can be restored by allogeneic lymphocytes.

Authors:  J D Schot; D Elferink; H Hooijkaas; H J Neijens; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.